Teva looks for $20B-plus from bond sale to finance Allergan deal


With the close of its $40 billion acquisition of Allergan’s generic unit nearing, Teva is drumming up some financing.

The Israeli generics giant plans to raise between $20 billion and $25 billion next week, Israeli newspaper Globes reports. In an SEC filing, the company said it would conduct investor calls in the U.S. this week and meetings in Europe next week ahead of a potential bond sale, and it’s brought on Barclays, Bank of America Merrill Lynch, BNP Paribas, Credit Suisse, HSBC and Mizuho to arrange the process.

The company is readying itself to seal the deal, which it struck last July. While the companies originally expected the acquisition to be wrapped by this year’s Q1, close scrutiny from U.S. antitrust regulators has forced the pair to extend their deadline and make a series of cast-offs.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Now, though, CEO Erez Vigodman expects to close the acquisition “at any time now,” he told investors on a Wednesday conference call. Other than the pending FTC go-ahead, “we are not aware of anything that would be expected to prevent the closing of this transaction,” he said.

Teva’s expecting big things from the buyout, which will solidify its place at the top of the generics heap. Wednesday, it predicted it could rake in $22 billion to $22.5 billion in 2016 revenue; $25.2 billion to $26.2 billion in 2017 revenue; $25.8 billion to $26.9 billion in 2018 revenue; and $26.7 billion to $27.8 billion in 2019 revenue, numbers Bernstein analyst Ronny Gal called “high.”

“If Teva is able to meet the expectations they projected today, then we’ll be seeing fantastic execution,” he wrote in a note to clients, noting that it’s “now a confidence-building exercise to show they can meet numbers.”

- here's the Globes story
- see the SEC filing
- read the call transcript

Special Reports: Top 20 generics companies by 2014 revenue - Teva - Allergan

Related Articles:
Teva expects Allergan deal close any day, it says while lifting guidance
Analyst cuts Allergan generics sales estimates as Teva deal close nears​
Teva, Allergan generics deal on track to close in June: Analyst
Teva hits roadblock in Allergan buy, hindering 'Pfizergan'
Teva speeds toward Allergan deal close with EU thumbs up
Teva mulls $7B stock offering to help fund Allergan generics buy
Forget Mylan: Teva inks $40B-plus pact for Allergan's generics biz

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.